Capricor Therapeutics is trading 10.1% down now at $6.14 after new securities-fraud class-action announcements and activist investor Kaos Capital’s demand for board changes.
- The legal claims allege misleading statements about Deramiocel’s clinical data and statistical-analysis plan.
- The FDA’s August 22, 2026 decision deadline follows a 9-3 advisory-panel vote against effectiveness.
- Shares fell 14.35% on August 20 while broader biotechnology markets rose, indicating company-specific pressure.